Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).

MLA

Egeberg, Alexander, and Jacob P. Thyssen. “Increased Reporting of Cerebrovascular Accidents with Use of Risankizumab Observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).” The British Journal of Dermatology, vol. 188, no. 6, May 2023, pp. 793–94. EBSCOhost, https://doi.org/10.1093/bjd/ljad039.

APA

Egeberg, A., & Thyssen, J. P. (2023). Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS). The British Journal of Dermatology, 188(6), 793–794. https://doi.org/10.1093/bjd/ljad039

Chicago

Egeberg, Alexander, and Jacob P Thyssen. 2023. “Increased Reporting of Cerebrovascular Accidents with Use of Risankizumab Observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).” The British Journal of Dermatology 188 (6): 793–94. doi:10.1093/bjd/ljad039.